9860 Stock Overview
Operates medical laboratories in the People’s Republic of China.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 1/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 9860 from our risk checks.
Adicon Holdings Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$9.29 |
| 52 Week High | HK$19.18 |
| 52 Week Low | HK$7.16 |
| Beta | 0 |
| 11 Month Change | -6.45% |
| 3 Month Change | 9.94% |
| 1 Year Change | -43.42% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -32.68% |
Recent News & Updates
Shareholder Returns
| 9860 | HK Healthcare | HK Market | |
|---|---|---|---|
| 7D | -0.3% | -4.0% | -2.9% |
| 1Y | -43.4% | -35.2% | -1.5% |
Return vs Industry: 9860 underperformed the Hong Kong Healthcare industry which returned -35.2% over the past year.
Return vs Market: 9860 underperformed the Hong Kong Market which returned -1.5% over the past year.
Price Volatility
| 9860 volatility | |
|---|---|
| 9860 Average Weekly Movement | 8.5% |
| Healthcare Industry Average Movement | 5.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in HK Market | 13.1% |
| 10% least volatile stocks in HK Market | 3.3% |
Stable Share Price: 9860 has not had significant price volatility in the past 3 months.
Volatility Over Time: 9860's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 5,713 | Song Gao | www.adicon.com.cn |
Adicon Holdings Limited operates medical laboratories in the People’s Republic of China. The company offers medical testing, clinical trials, scientific research services, health management, and pathological consultation services. It is also involved in the trading of medical testing equipment.
Adicon Holdings Limited Fundamentals Summary
| 9860 fundamental statistics | |
|---|---|
| Market cap | HK$6.55b |
| Earnings (TTM) | HK$246.58m |
| Revenue (TTM) | HK$3.42b |
27.3x
P/E Ratio2.0x
P/S RatioIs 9860 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 9860 income statement (TTM) | |
|---|---|
| Revenue | CN¥3.12b |
| Cost of Revenue | CN¥1.86b |
| Gross Profit | CN¥1.26b |
| Other Expenses | CN¥1.04b |
| Earnings | CN¥224.66m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.31 |
| Gross Margin | 40.42% |
| Net Profit Margin | 7.20% |
| Debt/Equity Ratio | 62.6% |
How did 9860 perform over the long term?
See historical performance and comparison